NCT00441376View on ClinicalTrials.gov

A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

December 31, 2009

Conditions

Hepatocellular CarcinomaLiver Neoplasms

Interventions

DRUG

ThermoDox

15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.

Trial Locations (1)

11030

Northshore Hospital - Long Island Jewish Health System, Manhasset